Markets

Validea's Top Five Healthcare Stocks Based On Martin Zweig - 7/19/2020

The following are the top rated Healthcare stocks according to Validea's Growth Investor model based on the published strategy of Martin Zweig. This strategy looks for growth stocks with persistent accelerating earnings and sales growth, reasonable valuations and low debt.

ALIGN TECHNOLOGY, INC. (ALGN) is a large-cap value stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Martin Zweig is 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Align Technology, Inc. designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment. The Clear Aligner segment consists of its Invisalign System, which includes Invisalign Full, Teen and Assist (Comprehensive Products), Express/Lite (Non-Comprehensive Products) and Vivera Retainers, along with its training and ancillary products for treating malocclusion (Non-Case). The Scanner segment consists of intra-oral scanning systems and other services available with the intra-oral scanners that provide digital alternatives to the traditional cast models. The Scanner segment includes its iTero scanner and OrthoCAD services.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

P/E RATIO:PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH:PASS
SALES GROWTH RATE:FAIL
CURRENT QUARTER EARNINGS:PASS
QUARTERLY EARNINGS ONE YEAR AGO:PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER:PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS:FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS:PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE:PASS
EARNINGS PERSISTENCE:PASS
LONG-TERM EPS GROWTH:PASS
TOTAL DEBT/EQUITY RATIO:PASS
INSIDER TRANSACTIONS:PASS

Detailed Analysis of ALIGN TECHNOLOGY, INC.

Full Guru Analysis for ALGN>

Full Factor Report for ALGN>

ALPHA PRO TECH, LTD. (APT) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Martin Zweig is 77% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: ALPHA PRO TECH, LTD. (Alpha Pro Tech) is in the business of protecting people, products and environments. The Company is engaged in developing, manufacturing and marketing a line of disposable protective apparel and infection control products for the cleanroom, industrial, pharmaceutical, medical and dental markets through its subsidiary, Alpha Pro Tech, Inc. Its products are grouped into three segments: Building Supply, which consists of construction weatherization products, such as housewrap and synthetic roof underlayment, as well as other woven material; Disposable Protective Apparel, which consists of disposable protective apparel, such as shoecovers, bouffant caps, gowns, coveralls, lab coats, frocks and other miscellaneous products, and Infection Control, which consists of face masks and eye shields. The Company also manufactures a line of building supply construction weatherization products through its subsidiary, Alpha ProTech Engineered Products, Inc.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

P/E RATIO:PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH:FAIL
SALES GROWTH RATE:PASS
CURRENT QUARTER EARNINGS:PASS
QUARTERLY EARNINGS ONE YEAR AGO:PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER:PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS:FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS:PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE:PASS
EARNINGS PERSISTENCE:FAIL
LONG-TERM EPS GROWTH:PASS
TOTAL DEBT/EQUITY RATIO:PASS
INSIDER TRANSACTIONS:PASS

Detailed Analysis of ALPHA PRO TECH, LTD.

Full Guru Analysis for APT>

Full Factor Report for APT>

CHINA BIOLOGIC PRODUCTS HOLDINGS INC (CBPO) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Martin Zweig is 77% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: China Biologic Products Holdings, Inc. is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company's products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

P/E RATIO:PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH:PASS
SALES GROWTH RATE:PASS
CURRENT QUARTER EARNINGS:PASS
QUARTERLY EARNINGS ONE YEAR AGO:PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER:PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS:FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS:PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE:PASS
EARNINGS PERSISTENCE:FAIL
LONG-TERM EPS GROWTH:FAIL
TOTAL DEBT/EQUITY RATIO:PASS
INSIDER TRANSACTIONS:PASS

Detailed Analysis of CHINA BIOLOGIC PRODUCTS HOLDINGS INC

Full Guru Analysis for CBPO>

Full Factor Report for CBPO>

THE ENSIGN GROUP, INC. (ENSG) is a mid-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Martin Zweig is 77% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Ensign Group, Inc., through its operating subsidiaries, provides healthcare services. The Company's operating subsidiaries provide a spectrum of skilled nursing services, physical, occupational and speech therapies and other rehabilitative and healthcare services The Company operates approximately 225 healthcare facilities across Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. Its skilled nursing companies provides skilled nursing care at approximately 216 operations in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. The Company holds a membership interest of mobile ancillary operations located in Arizona, California, Colorado, Idaho and Utah.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

P/E RATIO:PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH:FAIL
SALES GROWTH RATE:PASS
CURRENT QUARTER EARNINGS:PASS
QUARTERLY EARNINGS ONE YEAR AGO:PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER:PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS:PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS:PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE:PASS
EARNINGS PERSISTENCE:FAIL
LONG-TERM EPS GROWTH:PASS
TOTAL DEBT/EQUITY RATIO:PASS
INSIDER TRANSACTIONS:PASS

Detailed Analysis of THE ENSIGN GROUP, INC.

Full Guru Analysis for ENSG>

Full Factor Report for ENSG>

ELI LILLY AND CO (LLY) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Martin Zweig is 77% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

P/E RATIO:PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH:FAIL
SALES GROWTH RATE:PASS
CURRENT QUARTER EARNINGS:PASS
QUARTERLY EARNINGS ONE YEAR AGO:PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER:PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS:PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS:PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE:PASS
EARNINGS PERSISTENCE:FAIL
LONG-TERM EPS GROWTH:PASS
TOTAL DEBT/EQUITY RATIO:FAIL
INSIDER TRANSACTIONS:PASS

Detailed Analysis of ELI LILLY AND CO

Full Guru Analysis for LLY>

Full Factor Report for LLY>

More details on Validea's Martin Zweig strategy

About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. Zweig has managed both mutual and hedge funds during his career, and he's put the fortune he's compiled to some interesting uses. He has owned what Forbes reported was the most expensive apartment in New York, a $70 million penthouse that sits atop Manhattan's Pierre Hotel, and he is a collector of all sorts of pop culture and historical memorabilia -- among his purchases are the gun used by Clint Eastwood in "Dirty Harry", a stock certificate signed by Commodore Vanderbilt, and even two old-fashioned gas pumps similar to those he'd seen at a nearby gas station while growing up in Cleveland, according to published reports.

About Validea: Validea is an investment research service that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ALGN APT ENSG LLY

Latest Markets Videos

    Validea

    At Validea we believe the best way to outperform the market is to follow the investment factors and strategies that have done so over long periods of time. Since 2003, our team has been dedicated to bringing the fundamental strategies of great investors and academics to the professional and retail investment communities via the tools, portfolios and research found on Validea.

    Learn More